報價延遲最少15分鐘:2025/07/20 16:40 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.39 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.01/-1.95
|
|
企業價值
469.97M
|
| 資產負債 |
|
每股賬面淨值
3.80
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 16:40 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |
